ClinicalTrials.gg
RecruitingNCT07108920FEMFALLTOXUpdated Sep 22, 2025

Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait

An observational study in Botulinum Toxin Injection, Stiff Knee Gait and Fall Risk, sponsored by Hopital Nord Franche-Comte. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Hopital Nord Franche-Comte · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Muscular spastic complications of the legs can alter significantly the ability to walk because it clinically manifests itself by a stiffness of the leg, thus generating a complication called "Stif Knee Gait" (SKG). It means that the femoro-patello-tibial articulation cannot be mobilized as it should because it stays spastic instead of being mobile.

However, it remains possible to treat this kind of medical condition by using Botulinum toxin injections in the target muscle, in particular the rectus femoris (which is part of the quadriceps).

As a reminder, botulinum toxin, sold under the international common denomination "Botox®", is a neurotoxin of 150 kDa produced by the bacteria "Clostridium Botulinum" and is the most powerful natural poison known to humankind, with its DL50 between 1 and 2 nanogramms / kg in humans. This toxin works by entering the neuro-muscular synaptic junctions and by linking itself to a proteic complex called SNARE. The link between the toxin and the SNARE complex inhibits the fusion of the acetylcholinergic synaptic vesicles with the plasmic membrane of the pre-synaptic axone. The Botox® blocks the exocytosis of the acetycholin (Ach) vesicle in the inter-synaptic space at the neuro-muscular junction and blocks the nervous transmission, thus generating muscular flaccid paralysis. This kind of intoxication is caused directly by an infection by Clostridium Botulinum and is called Botulism. It manifests itself clinically by flaccid paralysis, swelling, diarrhea tiredness, respiratory failure, vomiting etc…

Despite its highly toxic properties, Botox® can be used as a therapeutic tool against number of medical conditions (strabismus, hyperhidrosis, migraines etc…) and even as a cosmetic tool (anti face-wrinkles). It can be used against spastic muscular paralysis, especially like the ones encountered in the patients of this study.

The current Standard Of Care (SOC) against SKG is to inject Botox into the rectus femoris in order to counter its spasticity. It has been shown to upgrade the walking ability of SKG patients by enhancing the leg kinetics. More precisely, it has been shown to improve the fluidity of the movement of the spastic leg in SKG patients, especially the knee flexion. However, the rectus femoris' contractility remains necessary to be able to stand up statically and to stay balanced during the walk and everyday-activity and the myorelaxant properties of Botox® may be problematic and alter the leg biomechanics despite its utility. To this day, no study has been published to compare the static and dynamic balance troubles before and after Botox injections in the rectus femoris.

The medical bibliography does not report any augmentation of the risk of fall in the case of Botox injection in the rectus femoris. However, we consider the hypothesis along which those injections can enhance the risk of fall. Therefore, we decided to conduct a monocentric, prospective observational clinical study to compare the state of the static and dynamic balance before and after Botox injections in the rectus femoris (in SKG patients) by using balance scores.

In order to complete this objective, we compared the following parameters before and after the Botox injection in SKG patients :

  • Time Up and Go test(in seconds) : primary evaluation criteria
  • Berg Balance Scale (BBS) : secondary evaluation criteria
  • Stair climb and descent time test (SCT) : secondary evaluation criteria.
  • Number of falls.
02

Conditions studied

  • Botulinum Toxin Injection
  • Stiff Knee Gait
  • Fall Risk
  • Rectus Femoris Muscle
  • Botox Injection
  • Spasticity With Multiple Sclerosis

Browse trials for

Keywords

  • Botulinum toxin injection
  • Rectus femoris
  • Balance troubles
  • Fall risk analysis
  • Stiff knee gait patients.
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's planned enrollment of 15 is below the median of 100 across 970 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Hopital Nord Franche-Comte is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients consists in patients suffering from a stiff knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis, and who never underwent any neurosurgical procedure and didn't ever change their anti-spastic treatments.

Those patients will be seen only in hospital structure (readaptation center) and never outside (liberal practice).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a stif knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis.
  • If the patient had a stroke, it happened at least 4 month ago (before the inclusion).
  • The patient has a rectus femoris spasticity ≥ 1 on the modified Ashworth Scale with the hip in extension position.
  • A quadricipital muscular force ≥ 2/5 (MRC Scale)
  • The patient didn't receive any botulinum toxin injection during the 3 previous months
  • No modification of any anti-spastic medication during the inclusion in the actual month (Baclofène, Dantrolène).
  • No neurosurgical intervention or ligamentoplasty of the quadricipital ligament during the 6 previous months.
  • No recent knee traumatism with knee instability during the 6 previous weeks.

Exclusion criteria

Exclusion Criteria:

  • Other comorbidities invalidating the fonctionnal tests necessary for the study like : decompensated cardiac insufficiency, unstable respiratory insufficiency, coagulation troubles, neurocognitive impairments inhibiting the comprehension of isocinetical tests.
  • Patient without severe phasic trouble inhibiting the patient's ability to answer the evaluation scales.
  • Sensory lesions inhibiting the possibility to evaluate the walk : visual impairment, major proprioception impairment, or cerebellar ataxia.
  • Severe muscular deficit : genetic myopathy, psychomotric desadaptation syndrom
  • Absolute to botulinum toxin injections : urinary tract infection ; current treatment by aminoglycosidic antibiotics, severe myasthenia, urine retention in patient who can't receive a urinary catheter.
  • Patient with cognitive troubles compromitting the understanding and the realization of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients treated with botulinum toxin injection in the rectus femoris.

    Other: Functional clinical tests

Interventions

  • OtherFunctional clinical tests

    Functional clinical tests: * Time Up and Go test * Berg Balance Scale (BBS) * Stair climb and descent time test (SCT) * Number of falls via a questionnaire

06

What researchers measure

Primary outcomes

  1. Time Up and Go test.

    This examination consist in 6 steps : 1. Sit on a chair 2. Stand up 3. Walk 3 meters 4. Make a U-turn 5. Walk back to the chair 6. Sit back. The investigator mesures (with a chronometer) the time it takes for the patient to complete the test. The timer starts when the patient stands up, and stops when the patient sits back.

    Time frame: Realized only once 4 weeks after the inclusion visit.

Secondary outcomes

  1. Assessment of Berg Balance Scale test.

    The Berg Balance Scale tests consists in assessing the ability of the patient to perform 14 tasks : * 1 : to stand up of a chair without using hands * 2 : to stand up without support * 3 : To sit without support, feet on the floor

    Time frame: 4 weeks after the Botulinum toxin injection visit.

07

Study locations

1 of 1 sites recruiting
  • Centre de Médecine Physique et de Réadaptation Bretegnier
    Héricourt, Nord Franche-Comté 70 400, France
    Recruiting
    • Jean-Philippe JP Ehny, M.D · ContactJPEHNY@fondation-arcenciel.fr · +33 84 46 57 91
    • Jean-Philippe JP Dr. Ehny, M.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07108920
Lead sponsor
Hopital Nord Franche-Comte
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Sep 22, 2025

Study contacts

Jean-Philippe JP Ehny, M.D
Contact
JPEHNY@fondation-arcenciel.fr
+33 84 46 57 91

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion